The relationship between the response to chemotherapy with cyclophosphamide, epirubicin and fluorouracil as well as the time to progression of metastasised breast cancer and DNA ploidy and S-phase fraction (SPF) of primary tumours was examined using paraffin-embedded tumour tissue from 81 patients. The response to chemotherapy was significantly better in patients with tumours with a high SPF, and in addition the time to progression was longer in the high-SPF group. There was no significant difference when the DNA ploidy and response to treatment were compared.
The knowledge of prognostic factors in early breast cancer has grown rapidly in recent years. Both node-negative and node-positive breast cancer patients contain identifiable subgroups with greatly different prognosis (Hedley et al., 1987; Sigurdsson et al., 1990; Ewers et al., 1991; Clark et al., 1992; Joensuu and Toikkanen, 1992) . Evidence from a large number of studies indicates an association between high Sphase fraction (SPF) and a shorter disease-free survival and overall survival of patients with breast cancer (Hedley et al., 1987; Kallioniemi et al., 1988; StAl et al., 1989; Toikkanen et al., 1989; Uyterlinde et al., 1990; Ewers et al., 1991; Joensuu and Toikkanen, 1992; O'Reilly et al., 1992; Clark et al., 1993) . Patients with aneuploid tumours also tend to have a worse prognosis than those with diploid tumours (Hedley et al., 1987; Kallioniemi et al., 1987; StAl et al., 1989; Toikkanen et al., 1989; Uyterlinde et al., 1990) . In most studies the SPF and DNA ploidy appear to be independent of tumour size, nodal status and steroid hormone receptor status. Owing to the strong association between high SPF, aneuploidy and histological grade, the independent prognostic significance of SPF and ploidy is sometimes lost when histological grade is included in a multivariate analysis (Toikkanen et al., 1989) .
The ability of DNA ploidy or SPF to predict the response to systemic treatment is a relatively unexplored area. There are four reports, involving a limited number of patients, on the ability of flow cytometry (FCM) of fine-needle aspirates to predict the chemosensitivity of primary breast tumours (Remvikos et al., 1989 (Remvikos et al., , 1993 Brifford et al., 1992; O'Reilly et al., 1992 In the only study in which the DNA ploidy and SPF of the primary breast tumour were compared with the chemotherapeutic response of the metastatic disease, no significant correlation was found (Masters et al., 1987) . Bonetti et al. (1994) found a positive correlation approaching statistical significance between the proliferative activity of the primary tumour measured by Ki-67 and the chemotherapeutic response of the metastatic disease. In the study of Sulkes et al. (1979) Two randomised groups of patients received the same monthly dose of 5-fluorouracil (500 mg m-2), epirubicin (60 mg m2) and cyclophosphamide (500 mg m-') either on a weekly or on a monthly basis. A total of 158 patients were evaluable for response. Tumour response was evaluated by International Union Against Cancer (UICC) criteria (Hayward et al., 1977) . For non-measurable but assessable lesions outside the skeleton only three categories were used: complete response (CR), no change (NC) and progressive disease (PD). The details of the trial methods and results have been published previously (Blomqvist et al., 1993) . The survival was significantly longer in the group treated once a month. Formalin-fixed, paraffin-embedded blocks from primary tumours of 88 patients were available for DNA flow cytometry. In 83 cases both SPF and DNA ploidy could be determined. Two of these cases were excluded later because of wrong diagnosis of advanced disease. The pretreatment characteristics of this subpopulation were similar to the total trial population (Table I) .
Flow cytometry A modification of the method of Hedley et al. (1983) was applied. In brief, two 50-jm-thick sections were treated with 10jg ml-' proteinase K (Sigma, St Louis, MO, USA) for 30 min at room temperature. After filtration, the nuclei were treated with I0 iLg ml'-RNAse and stained with 25 jig ml-I ethidium bromide (Sigma) for at least 1 h. The DNA was determined by FCM (FACScan, Becton Dickinson, Mountain View, CA, USA) using 200 mW excitation at 488 nm, and the total emission above 560 nm was recorded. As the staining intensity of fixed nuclei varies from one sample to another, no internal standard was added. The lowest peak was assigned a DNA index (DI) value of 1.00 and the DI values of other peaks were calculated with this as a reference.
Therefore, possible hypodiploid peaks were identified as dip-SW PS cmu --od-i yi brn crmmr P Hietanen et a loid and the normal diploid peak as hyperdiploid. Table II. No significant difference was seen when DNA ploidy and response to chemotherapy were compared either in all patients or in the two treatment groups separately. However, the time to progression was significantly longer in patients with diploid than in those with non-diploid tumours (P = 0.05) (Figure 1) .
A positive response to either type of chemotherapy was seen in only 6/34 (18%) patients with low-SPF tumours, whereas 17/38 (45%) patients with high-SPF tumours showed Figure 2 ) compared with the low-SPF group, and especially in those treated on a weekly basis (P = 0.03) (Figure 3 ). The disease-free interval from the diagnosis to the first recurrence was not significantly different in high-and low-SPF groups (13.0 and 19.0 months respectively, P=0.10). The median overall survival after the randomisation to chemotherapy was not significantly different in low-and high-SPF groups (16.1 and 16.8 months respectively) or for diploid and non-diploid tumours (17.0 and 16.1 months respectively).
An objective regression of advanced breast cancer can be achieved in approximately 50% of patients receiving chemotherapy (Blomqvist et al., 1993) . Chemotherapeutic agents are generally more active against cycling than noncycling cells in vitro (Drewinko et al., 1981) . Numerous studies have demonstrated a relatively small growth fraction in most human solid tumours, particularly breast tumours. Drug resistance is a central problem in cancer treatment, and it is therefore important to develop reliable criteria for the selection of those patients who benefit from chemotherapy.
In our study there was no significant difference comparing the DNA ploidy of the primary tumour and the response, although there was a non-significant trend towards a better response in diploid tumours. Previous studies in which DNA content and the response to chemotherapy have been correlated are contradictory. Our findings agree with those of Masters et al. (1987) , the only study in which DNA ploidy of the primary tumour and the response to chemotherapy of advanced disease has been correlated. Remvikos et al. (1989) , who correlated the response of the primary tumour to chemotherapy and DNA ploidy, did not find a significant difference. However, Brifford et al. (1989) and O'Reilly et al. (1992) observed a significantly higher response rate to combination chemotherapy in aneuploid than in diploid tumours.
The response rate did not correlate to the DNA ploidy of the primary tumours in our study, but the time to progression was significantly longer in patients with diploid tumours than in those with non-diploid tumours. This may be related to their less aggressive clinical course rather than due to the chemotherapy. The overall survival after randomisation did not differ between these groups.
In the present study the response to chemotherapy was significantly better in the high-SPF group. There was also a trend towards longer time to progression in the high-SPF group, which may be related to the better response to treatment in patients with these tumours, as the disease-free survival did not differ significantly in these groups. Our finding agrees with previous reports on improved chemotherapeutic response rates in primary tumours with high SPF (Osborne, 1989; Remvikos et al., 1989 Remvikos et al., , 1993 O'Reilly et al., 1992; Spyratos et al., 1992) and in advanced breast cancer, when primary tumours showed high proliferative activity measured by Ki-67 (Bonetti et al., 1994) and tumour cell uptake of tritiated thymidine (Sulkes et al., 1979) . While in our study the tumours of patients treated weekly showed less response as a whole to chemotherapy, the response rate of tumours with a high SPF was significantly better than that of tumours with a low SPF also in this group. Niskanen et al. (1993) found that an amplification of the c-erbB-2 gene predicts a favourable response in patients receiving chemotherapy on a weekly basis. This may indicate that patients with tumours with a high proliferation rate may benefit from a more frequent administration of drugs. The time to progression was significantly longer in the high-SPF group treated on a weekly basis, while no clear difference was seen with the treatment every fourth week. It will be important to verify our results in a study with more patients and with other chemotherapy regimens.
In conclusion, our results indicate that patients with advanced breast cancer who have primary tumours with a high SPF respond better to combination chemotherapy than patients with low-SPF tumours. An assessment of the SPF may assist in the selection of patients with advanced breast cancer for chemotherapy. This has to be confirmed in a study with more patients. 
